Nycomed extends GPO deal to Novation
Nycomed Amersham Imaging of Princeton, NJ, has extended its contrast agent supply relationships with group purchasing organizations VHA and University HealthSystem Consortium (UHC) to Novation, the new company formed to supply the GPOs. The extension
Nycomed Amersham Imaging of Princeton, NJ, has extended its contrast agent supply relationships with group purchasing organizations VHA and University HealthSystem Consortium (UHC) to Novation, the new company formed to supply the GPOs. The extension also incorporates new Nycomed contrast agents not covered in the previous deals, such as the companys Teslascan MRI liver imaging agent.
Nycomed Amersham previously had separate contrast supply deals with VHA of Irving, TX, and UHC of Oak Brook, IL. Those GPOs in January spun off their supply and purchasing organizations to form Novation, so Nycomed Amersham began negotiating a supply deal with the new entity.
The new agreement covers contrast agent purchasing for the next five years, beginning in January. It also includes provisions that should increase compliance among VHA and UHC members, according to a Nycomed Amersham spokesperson.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
